Search results for "Risk"

showing 10 items of 9963 documents

Are Adiponectin and Leptin Good Predictors of Surgical Infection after Colorectal Surgery? A Prospective Study

2015

Infections are the most frequent complication after colorectal surgery. It has been suggested that adipose tissue metabolism could be related to the risk of post-operative infection, but this could be partially related to the body-mass index. The aim of this study was to look for a relation between adipocytokine levels and the risk of post-operative infection and its type.This prospective cohort study was conducted between March 2013 and March 2014 in two French teaching hospitals. Pre-operative plasma levels of adiponectin and leptin were measured in consecutive patients undergoing elective colorectal surgery. All infections in the 30 d following surgery were recorded.Among the 142 patient…

AdultLeptinMaleMicrobiology (medical)medicine.medical_specialtyRisk AssessmentPlasmaInternal medicineHumansSurgical Wound InfectionMedicineProspective StudiesHospitals TeachingProspective cohort studyAgedAged 80 and overAdiponectinbusiness.industryLeptinMiddle AgedPrognosisColorectal surgerySurgeryInfectious DiseasesFemaleSurgeryAdiponectinFrancebusinessRisk assessmentComplicationColorectal SurgeryBody mass indexSurgical InfectionsSurgical Infections
researchProduct

Psychological and hormonal features of smokers at risk to gain weight after smoking cessation--results of a multicenter study.

2011

Preclinical and clinical data suggest modulating effects of appetite-regulating hormones and stress perception on food intake. Nicotine intake also interferes with regulation of body weight. Especially following smoking cessation gaining weight is a common but only partially understood consequence. The aim of this study was to examine the interaction between smoking habits, the appetite regulating hormone leptin, negative affectivity, and stress vulnerability on eating behavior in a clinical case-control study under standardized conditions. In a large population-based study sample, we compared leptin and cortisol plasma concentrations (radioimmunoassay) between current tobacco smokers with …

AdultLeptinMaleRiskmedicine.medical_specialtyHydrocortisonemedicine.medical_treatmentPerceived Stress ScaleAnxietyWeight GainNegative affectivityNicotineBehavioral NeuroscienceYoung AdultEndocrinologySurveys and QuestionnairesmedicineHumansPsychiatrySalivaEndocrine and Autonomic SystemsSmokingBeck Depression InventoryFeeding BehaviorMiddle AgedCase-Control StudiesSmoking cessationAnxietyFemaleSmoking Cessationmedicine.symptomPsychologyThree-Factor Eating QuestionnaireState-Trait Anxiety InventoryStress PsychologicalClinical psychologymedicine.drugHormones and behavior
researchProduct

Inflammatory markers and cardiovascular risk in the metabolic syndrome

2011

Elevated blood glucose, obesity, high blood pressure, elevated triglycerides and low high density lipoprotein (HDL) cholesterol are well accepted risk factors in the development of coronary artery disease. Clustering of at least three of these factors in an individual is defined as metabolic syndrome (MetS). Obesity is a central pathological mechanism in the disease and it is expected that the incidence of this condition will increase dramatically within the next years. The visceral adipose tissue is not only an energy depot but also an endocrine organ which produces a large number of bioactive molecules, the so called adipokines. In the setting of obesity, the over-production of proinflamm…

AdultLeptinRiskAdolescentAngiotensinogenAdipokineAdipose tissueDiseaseIntra-Abdominal FatBioinformaticsCoronary artery diseasePathogenesisInsulin resistancePlasminogen Activator Inhibitor 1medicineHumansResistinObesityLife StyleChemokine CCL2InflammationMetabolic SyndromeInterleukin-6Tumor Necrosis Factor-alphabusiness.industryAtherosclerosisPrognosismedicine.diseaseObesityPlaque AtheroscleroticCardiovascular DiseasesAdiponectinEndothelium VascularInsulin ResistanceMetabolic syndromebusinessBiomarkersFrontiers in Bioscience
researchProduct

"Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV".

2022

Objectives Non-alcoholic fatty liver disease (NAFLD) is strongly associated with cardiovascular disease in the general population. We aimed to assess the impact of NAFLD and liver fibrosis on intermediate-high cardiovascular risk in people living with HIV. Methods We included people living with HIV from three cohorts. NAFLD and significant liver fibrosis were defined using transient elastography: controlled attenuation parameter >= 288 dB/m and liver stiffness measurement >= 7.1 kPa, respectively. Cardiovascular risk was assessed with the atherosclerotic cardiovascular disease (ASCVD) risk estimator in patients aged between 40 and 75 years and categorised as low if <5%, borderline …

AdultLiver CirrhosisLiver CirrhosiHIV InfectionsBMIElasticity Imaging TechniqueNon-alcoholic Fatty Liver DiseaseRisk FactorsCardiovascular DiseaseHumansHIV InfectionPharmacology (medical)Prospective StudiesNon-alcoholic Fatty Liver Disease.AgedASCVD score; BMI; controlled attenuation parameter; HIV mono-infection; transient elastographyASCVD scoreRisk FactorHealth PolicyHIV mono-infectionHeart Disease Risk FactorMiddle Agedtransient elastographycontrolled attenuation parameterProspective StudieInfectious DiseasesLiverCardiovascular DiseasesHeart Disease Risk FactorsElasticity Imaging TechniquesHumanHIV medicineREFERENCES
researchProduct

Interaction of alcohol intake and cofactors on the risk of cirrhosis.

2010

OBJECTIVE: Evaluation of the interaction between alcohol intake and cofactors [hepatitis B virus (HBV), hepatitis C virus (HCV), body mass index] and coffee consumption on the risk of cirrhosis. DESIGN: Seven hundred and forty-nine consecutive patients with chronic liver disease referring to units for liver or alcohol diseases in Italy during a 6-months period. Teetotalers were excluded. The odds ratios (OR) for cirrhosis were evaluated using chronic hepatitis cases as the control group. RESULTS: An alcohol intake of more than 3 units/day resulted associated with the likelihood of cirrhosis both in males (OR 4.3; 95% CI=2.5-7.3) and in females (OR 5.7; 95% CI=2.3-14.5). A multiplicative int…

AdultLiver CirrhosisMaleHepatitis B virusAlcohol Drinkingalcohol cirrhosis coffeeHepacivirusCoffeeRisk Assessmentcirrhosis coffeeBody Mass IndexNORisk FactorsOdds RatioHumansCIRRHOSISAgedHepatitis B Surface AntigensalcoholHepatitis C AntibodiesMiddle AgedHepatitis BHepatitis CItalyCase-Control StudiesDisease ProgressionRNA ViralFemale
researchProduct

The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases

2005

Knowledge of the current epidemiology of chronic liver disease in Italy is mostly obsolete and fragmentary for the lack of up-to-date consistent data. In 2001, a 6-month prevalence study was undertaken in 79 hospitals to assess the characteristics of chronic liver disease in Italy. Both prevalent and incident cases were enrolled. A total of 9,997 patients were recruited, of whom 939 (9.4%) had normal liver biochemistry, 6,210 (62.1%) had chronic hepatitis, 1,940 (19.4%) had liver cirrhosis, and 341 (3.4%) had hepatocellular carcinoma (HCC). In 567 patients (5.7%) the diagnosis was not established. Hepatitis C virus (HCV) was found in 69.9% of the patients and was the only etiological factor…

AdultLiver CirrhosisMaleHepatitis B virusHBsAgCarcinoma HepatocellularCirrhosisalcohol abuseHepatitis C virusHepacivirusChronic liver diseasemedicine.disease_causeRisk FactorsVirologyPrevalencemedicineHBVHumansAgedbusiness.industryIncidenceLiver DiseasesLiver NeoplasmsHepatitis CMiddle AgedHepatitis BHepatitis Bmedicine.diseaseHepatitis CVirologyAlcoholismInfectious DiseasesItalyHepatocellular carcinomaChronic DiseaseHCVFemaleViral hepatitisbusiness
researchProduct

High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance

2004

The emergence of drug-resistant virus in hepatitis B virus patients treated with lamivudine is well documented. However. its clinical impact in the long-term treatment of anti-HBe positive compensated cirrhotic patients is not well known. In this study, we treated 22 consecutive patients with anti-HBe compensated cirrhosis with lamivudine for a median period of 42 months. All patients responded to lamivudine, but viral breakthrough occurred in 13 patients (59%) between 9 and 42 months of therapy due to the emergence of a mutant strain. During the follow-up, 11 developed hepatocellular carcinoma. Of these, 10 occurred soon after the emergence of viral resistance, generally showing aggressive…

AdultLiver CirrhosisMaleHepatitis B virusmedicine.medical_specialtyCarcinoma HepatocellularCirrhosisLAMIVUDINEmedicine.disease_causeRisk AssessmentGastroenterologyVirusVirologyInternal medicineDrug Resistance ViralHumansMedicineHepatitis B e AntigensHEPATOCELLULAR CARCINOMAHepatitis B AntibodiesCIRRHOISIS; HEPATOCELLULAR CARCINOMA; LAMIVUDINE; HEPATITIS B; PRE-CORE MUTANTHepatitis B virusCirrhosiHepatologybusiness.industryCIRRHOISISLamivudineMiddle AgedHepatitis Bmedicine.diseaseHepatitis B Core AntigensViral BreakthroughPRE-CORE MUTANTInfectious DiseasesHepatocellular carcinomaRelative riskMutationHEPATITIS BReverse Transcriptase InhibitorsFemalePrecore mutantbusinessmedicine.drugJournal of Viral Hepatitis
researchProduct

Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis

2009

GOALS AND BACKGROUND: The multikinase inhibitor sorafenib provides survival benefit for patients with advanced hepatocellular carcinoma (HCC) and liver cirrhosis (LCI) Child-Pugh A. We report our experiences with sorafenib in advanced HCC, particularly in patients with LCI Child-Pugh B/C, where only limited data are available in regard to safety and efficacy of sorafenib. METHODS: Thirty-four patients with advanced HCC were treated with sorafenib regardless of liver function and prior anticancer therapy. Adverse events (AEs) were graded using Common Toxicity Criteria version 3.0, tumor response was assessed according to Response Evaluation Criteria in Solid Tumors. RESULTS: Fifteen patients…

AdultLiver CirrhosisMaleNiacinamideSorafenibmedicine.medical_specialtyCarcinoma HepatocellularTime FactorsCirrhosisPyridinesAntineoplastic AgentsKaplan-Meier EstimateRisk AssessmentSeverity of Illness IndexGastroenterologyInternal medicinemedicineCarcinomaHumansProspective StudiesProtein Kinase InhibitorsAgedAged 80 and overbusiness.industryPatient SelectionPhenylurea CompoundsBenzenesulfonatesLiver NeoplasmsGastroenterologyCancerMiddle AgedSorafenibmedicine.diseasedigestive system diseasesSurgeryTreatment OutcomeResponse Evaluation Criteria in Solid TumorsHepatocellular carcinomaConcomitantFemaleLiver functionbusinessmedicine.drugJournal of Clinical Gastroenterology
researchProduct

Prognostic factors and outcomes of patients with hepatocellular carcinoma in non-cirrhotic liver

2012

To report the outcome of patients with hepatocellular carcinoma (HCC) in non-cirrhotic liver depending on the mode of primary treatment and to define clinicopathological factors influencing patients' prognosis.A retrospective analysis of an unselected cohort of 105 patients was performed. Overall survival (OS) was estimated by the Kaplan-Meier method and potentially prognostic factors were analyzed in Cox regression models.OS of the whole cohort at 1, 3, and 5 years was 66%, 47%, and 29%, respectively. Tobacco consumption, ECOG0, macroscopic vascular invasion, continuous tumor diameter, and treatment other than resection were predictors of decreased OS in the whole cohort. Resection was per…

AdultLiver CirrhosisMaleOncologymedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentAntineoplastic AgentsRisk FactorsInternal medicinemedicineCarcinomaHepatectomyHumansSurvival analysisAgedNeoplasm StagingRetrospective StudiesAged 80 and overProportional hazards modelbusiness.industryLiver NeoplasmsGastroenterologyRetrospective cohort studyMiddle AgedPrognosismedicine.diseaseSurvival AnalysisBCLC StageTreatment OutcomeLiverHepatocellular carcinomaCohortFemaleHepatectomybusinessFollow-Up StudiesScandinavian Journal of Gastroenterology
researchProduct

Assessing inter- and intra-individual cognitive variability in patients at risk for cognitive impairment: the case of minimal hepatic encephalopathy

2014

Recent evidence reveals that inter- and intra-individual variability significantly affects cognitive performance in a number of neuropsychological pathologies. We applied a flexible family of statistical models to elucidate the contribution of inter- and intra-individual variables on cognitive functioning in healthy volunteers and patients at risk for hepatic encephalopathy (HE). Sixty-five volunteers (32 patients with cirrhosis and 33 healthy volunteers) were assessed by means of the Inhibitory Control Task (ICT). A Generalized Additive Model for Location, Scale and Shape (GAMLSS) was fitted for jointly modeling the mean and the intra-variability of Reaction Times (RTs) as a function of so…

AdultLiver CirrhosisMaleRiskmedicine.medical_specialtyNeurologyCirrhosisPsychometricsLiver CirrhosiModels NeurologicalIndividualityReproducibility of ResultInter-intra individual differenceNeuropsychological TestsAudiologyBiochemistryGeneralized linear mixed modelCognition DisorderCellular and Molecular NeuroscienceReaction TimemedicineHumansSub-clinical brain impairmentEffects of sleep deprivation on cognitive performanceHepatic encephalopathyAgedSubclinical infectionCirrhosiSettore M-PSI/02 - Psicobiologia E Psicologia FisiologicaNeuropsychologyReproducibility of ResultsCognitionMiddle Agedmedicine.diseaseSurgeryHepatic EncephalopathyCognitive controlNeuropsychological TestFemaleNeurology (clinical)Cognition DisordersPsychologyPsychometricPsychomotor PerformanceHuman
researchProduct